Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890417433> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2890417433 abstract "7039 Background: HMAs are an accepted frontline therapy for AML patients (pts) who are unfit for intensive induction therapy (IIT), particularly pts with unfavorable cytogenetics and/or p53 mutations. However, little is known about the response of favorable risk AML to HMAs. We previously reported that NPM1 mutated and/or CD34- AML status were predictors of response to HMAs. Here, we evaluated responses to frontline HMAs in AML. Methods: A total of 117 patients with de novo AML diagnosed between 7/2013 and 9/2016 were evaluated based on pt and disease related variables, overall response rate (ORR = CR + CR with incomplete count recovery + hematologic remission (ANC > 1000/µL, Hgb > 10g/dL, Plts > 100,000/µL, & no circulating blasts)), and overall survival (OS). Categorical variables were compared using Fisher’s exact test. Kaplan Meier methods estimated survival outcomes, and log rank tests compared survival between groups. Multivariable analyses were performed using Cox proportional hazards models. Results: 51 pts, considered unfit for IIT, received frontline HMAs. ORR and OS were highest in the ELN favorable risk AML pts (n = 13; ORR = 92%, p = .009; median OS = 17.5 months, p = .022). Among 41 NPM1 mutated pts, 15 received HMAs; and 26 received intensive induction. ORRs were 73% and 84%, respectively (p = .434). No difference was found in OS distributions between the HMA and IIT groups in univariate and multivariate (adjusted for age and FLT3 status) models (p = .329 and .241, respectively). Interestingly, ORR was 100% among 9 HMA-treated pts with NPM1 mutated, CD34-, FLT3/ITD-, cytogenetically normal AML. Conclusions: HMA therapy is highly effective frontline treatment in favorable risk AML pts considered unfit for IIT. Survival results with HMAs in NPM1 mutated AML are comparable to those of fitter pts treated with IIT. In selected favorable risk pts considered unfit for standard induction, HMAs can be a successful bridge to potentially curative therapy, including more intensive therapy or transplant. Cytogenetically normal AML with an isolated NPM1 mutation and CD34- status appears to be exceptionally responsive to frontline treatment with HMAs. Prospective validation of these findings is necessary." @default.
- W2890417433 created "2018-09-27" @default.
- W2890417433 creator A5006044740 @default.
- W2890417433 creator A5014805012 @default.
- W2890417433 creator A5018065917 @default.
- W2890417433 creator A5019444571 @default.
- W2890417433 creator A5030734452 @default.
- W2890417433 creator A5042176968 @default.
- W2890417433 creator A5048128189 @default.
- W2890417433 creator A5056869531 @default.
- W2890417433 creator A5059818015 @default.
- W2890417433 creator A5059850025 @default.
- W2890417433 creator A5080870057 @default.
- W2890417433 creator A5085005519 @default.
- W2890417433 creator A5087346651 @default.
- W2890417433 date "2017-05-20" @default.
- W2890417433 modified "2023-10-18" @default.
- W2890417433 title "Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML." @default.
- W2890417433 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7039" @default.
- W2890417433 hasPublicationYear "2017" @default.
- W2890417433 type Work @default.
- W2890417433 sameAs 2890417433 @default.
- W2890417433 citedByCount "0" @default.
- W2890417433 crossrefType "journal-article" @default.
- W2890417433 hasAuthorship W2890417433A5006044740 @default.
- W2890417433 hasAuthorship W2890417433A5014805012 @default.
- W2890417433 hasAuthorship W2890417433A5018065917 @default.
- W2890417433 hasAuthorship W2890417433A5019444571 @default.
- W2890417433 hasAuthorship W2890417433A5030734452 @default.
- W2890417433 hasAuthorship W2890417433A5042176968 @default.
- W2890417433 hasAuthorship W2890417433A5048128189 @default.
- W2890417433 hasAuthorship W2890417433A5056869531 @default.
- W2890417433 hasAuthorship W2890417433A5059818015 @default.
- W2890417433 hasAuthorship W2890417433A5059850025 @default.
- W2890417433 hasAuthorship W2890417433A5080870057 @default.
- W2890417433 hasAuthorship W2890417433A5085005519 @default.
- W2890417433 hasAuthorship W2890417433A5087346651 @default.
- W2890417433 hasConcept C104317684 @default.
- W2890417433 hasConcept C126322002 @default.
- W2890417433 hasConcept C143998085 @default.
- W2890417433 hasConcept C150194340 @default.
- W2890417433 hasConcept C190727270 @default.
- W2890417433 hasConcept C2776012956 @default.
- W2890417433 hasConcept C2776239401 @default.
- W2890417433 hasConcept C2780235182 @default.
- W2890417433 hasConcept C54355233 @default.
- W2890417433 hasConcept C71924100 @default.
- W2890417433 hasConcept C86803240 @default.
- W2890417433 hasConceptScore W2890417433C104317684 @default.
- W2890417433 hasConceptScore W2890417433C126322002 @default.
- W2890417433 hasConceptScore W2890417433C143998085 @default.
- W2890417433 hasConceptScore W2890417433C150194340 @default.
- W2890417433 hasConceptScore W2890417433C190727270 @default.
- W2890417433 hasConceptScore W2890417433C2776012956 @default.
- W2890417433 hasConceptScore W2890417433C2776239401 @default.
- W2890417433 hasConceptScore W2890417433C2780235182 @default.
- W2890417433 hasConceptScore W2890417433C54355233 @default.
- W2890417433 hasConceptScore W2890417433C71924100 @default.
- W2890417433 hasConceptScore W2890417433C86803240 @default.
- W2890417433 hasLocation W28904174331 @default.
- W2890417433 hasOpenAccess W2890417433 @default.
- W2890417433 hasPrimaryLocation W28904174331 @default.
- W2890417433 hasRelatedWork W1978355894 @default.
- W2890417433 hasRelatedWork W1983743831 @default.
- W2890417433 hasRelatedWork W1992275797 @default.
- W2890417433 hasRelatedWork W2295627690 @default.
- W2890417433 hasRelatedWork W2525202632 @default.
- W2890417433 hasRelatedWork W2593683827 @default.
- W2890417433 hasRelatedWork W2601464395 @default.
- W2890417433 hasRelatedWork W2782457553 @default.
- W2890417433 hasRelatedWork W2890018217 @default.
- W2890417433 hasRelatedWork W2903652141 @default.
- W2890417433 hasRelatedWork W2912054581 @default.
- W2890417433 hasRelatedWork W2914784540 @default.
- W2890417433 hasRelatedWork W2945124588 @default.
- W2890417433 hasRelatedWork W2969301146 @default.
- W2890417433 hasRelatedWork W2997524822 @default.
- W2890417433 hasRelatedWork W3043868243 @default.
- W2890417433 hasRelatedWork W3133178773 @default.
- W2890417433 hasRelatedWork W3137559923 @default.
- W2890417433 hasRelatedWork W3163450469 @default.
- W2890417433 hasRelatedWork W3209025873 @default.
- W2890417433 isParatext "false" @default.
- W2890417433 isRetracted "false" @default.
- W2890417433 magId "2890417433" @default.
- W2890417433 workType "article" @default.